Gilead Stock News

Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.

Gilead is a biotech company with a recession-resistant portfolio and a reasonable valuation. Kroger is a Warren Buffett stock that produces reliable cash flows.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August

Gilead Sciences Inc. GILD, +0.43% said Friday the U.S. Food and Drug Administration has approved the use of its Veklury, or remdesivir, for patients with severe renal impairment, including those on di

In recent Securities & Exchange Commission filings, Gilead Sciences Inc. NASDAQ: GILD revealed that it had purchased significant stakes in AlloVir Inc. NASDAQ: ALVR and Arcus Biosciences Inc. NYSE: RC

Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated

Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.

As most savvy investors know by now, the outperformance of the Nasdaq and to a lesser degree, the S&P 500 has been driven by seven mega-caps, hailing from the tech, consumer discretionary, and communi

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th

Although it's been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at

Likely, 2023 will be known as the year artificial intelligence became a permanent part of the investing lexicon.

With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.

In my last article, I said I liked Nurix, a protein degrader company. Since then, not much has happened at Nurix except Gilead buying into an asset. This is a validation of the company, however, there

Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.

Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.